Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter - Monday, August 4, 2025
Stock Region Penny Picks Watchlist Newsletter - Monday, August 4, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The information provided in this newsletter is for informational purposes only and should not be considered financial advice. Always do your own due diligence before investing or consult with a professional if needed.
Hello Stock Region Members! 🌟
Brace yourselves, because yesterday was an action-packed day on Wall Street! If you love a mix of bold moves, exciting partnerships, and game-changing headlines, this edition will have you buzzing. Let's dig into the latest developments that should be on your radar.
🔄 $BLDE (Blade Air Mobility)
Blade is taking a big leap by selling off its Passenger Division to Joby. What’s the plan here? They’re going all-in on becoming a pure-play medical services and logistics company. While some might see narrowing focus as risky, it could make Blade a force to reckon with in a highly specialized market. This pivot could mean a leaner, more efficient business—but will investors buy into the new vision? It’s definitely worth watching.
🤝 $ATCH (AtlasClear Holdings, Inc.)
AtlasClear announced an investment partnership with Dawson James, signaling a strategic move to ramp up growth. This partnership shows they mean business, but it also leaves us wondering how quickly this will bear fruit. Keep an eye on this one—it has potential written all over it, especially if both parties play their cards right.
💸 $PEW (GrabAGun)
Big news from GrabAGun! They’ve greenlit a $20 million share repurchase program, which is often a confident move by companies signaling that they believe their current valuation is undervalued. Does this mean they’re planning to silence critics and boost shareholder value? It sure sounds like it. Time to lock and load this ticker on your watchlist!
🚨 $INMB (INmune Bio)
INmune Bio’s INKmune™ really hit the mark in its CaRe PC trial for metastatic castration-resistant prostate cancer. The trial meeting its endpoints and closing enrollment could be a solid win in the always-competitive biotech space. Early-stage success looks promising, but tread cautiously—it’s still a bumpy road from trials to the market.
💰 $VERB (Verb Technology Company)
Get ready, because Verb is thinking big! With a $558 million private placement, they’re set to create the first publicly listed TON Treasury Strategy company. Now, I won’t sugarcoat it—this is complex and could raise eyebrows, but it’s bold and ambitious. If you like plays with high risk and high reward, this one might pique your interest.
🚀 $SNGX (Soligenix)
Soligenix is making waves with wins in late-stage therapeutic pipelines, which is driving confidence in high-growth therapeutic areas. For those who love biotech plays with potential upside, this might be something to check out sooner rather than later.
🔗 $BTBD (BT Brands)
BT Brands isn't sitting still—they’re exploring strategic initiatives, even entertaining a potential merger. If executed well, this could unlock value for investors. Time will tell if they can pull off a deal that excites the market.
✅ $CASI (CASI Pharmaceuticals)
CASI's FDA clearance for an IND application for CID-103 targeting Renal Allograft Antibody-Mediated Rejection is another step in the right direction for their pipeline. FDA approvals are no small feat, so this milestone could tell us something about their momentum. Bulls might want to take note!
📈 $BMRN (BioMarin Pharmaceutical)
BioMarin crushed its second-quarter numbers and even raised its full-year guidance. This is the kind of bullish news investors love to hear. With strong performance like this, BioMarin looks like it’s got plenty of runway to impress. Bagholders, rejoice!
💹 $ARDX (Ardelyx)
Closing out with a bang, Ardelyx reported a 33% year-over-year revenue growth for Q2, bringing in an impressive $97.7 million. Solid financials like this can drive sustained momentum, and it’s clear Ardelyx is doing something right. Growth-focused investors, don’t sleep on this.
Markets are constantly shifting, and keeping an eye on game-changing moves like these can give you an edge. Whether you’re into biotech, growth, or value plays, this week’s watchlist has something for everyone. Whatever you do, remember there’s no such thing as a sure thing in the market—hype can be as much a friend as it is an enemy.
Until next time, stay savvy, Stock Region! 🚀
Disclaimer: The stock market involves risks, and the above commentary is not to be considered a solicitation to buy or sell any security. Always consult with a trusted financial advisor to align your investment decisions with your personal financial situation.